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Earlier this year, the Pharmacy Guild of Australia announced the restructure of the 
Home Medicine Review (HMR) program. The new funding provision of this program 
requires a minimum two-year interval between each review conducted for a specific 
patient. Significant debate has arisen about the potential implications this will have on 
all stakeholders, particularly consumers, and on the incidence of medication errors and 
use of health care resources. The Pharmacy guild has announced that the changes will 
"ensure the ongoing viability" of the program and as part of this they will also work to
identify patients who will most benefit from HMR services.1 
This RESEARCH ROUNDup provides a brief overview of the current evidence of the 
benefits and limitations of HMRs and discusses cohorts of patients who might be 
targeted to maximise HMR benefits. 
experienced an adverse drug reaction (ADR) within the previous 
six months, and 11% of these were categorised as severe.11 
A recent review of medication safety in Australia found growing 
evidence in the community for the benefits of multidisciplinary 
approaches to improving medication management including 
collaborative home medicines reviews.9 These benefits extend 
beyond the prevention and resolution of ADRs, and include the 
opportunity to educate, identify and resolve issues associated 
with suboptimal patient understanding of their medicines, 
underuse of medicines and untreated indications.2,5,12,13 HMRs 
have been shown to enhance the continuity of care between 
tertiary and primary care through medication reconciliation, thus 
improving the transition between hospital and community care, 
which is a risk factor for further hospitalisations.14,15 
Cost-effectiveness of the HMR program 
The Value of Medication Reviews (VALMER) study, undertaken to 
assess the clinical and economic outcomes of HMRs in Australia, 
demonstrated minimal short-term (12 months) economic 
benefits associated with HMRs in the context of a broad range of 
patients. Specifically, although HMRs were associated with 
significant reductions in health care utilisation costs and 
improved quality of life, only negligible average net savings 
would be conferred within the short-term, and HMRs were not 
found to be cost-effective overall.2 However, just 16% of 
VALMER patients accounted for most of the savings.2 For 
VALMER study patients associated with savings in the upper 
quartile, the average calculated saving was $632.15, versus an 
average HMR cost of $323.80 (Guild final report VALMER 2009).2 
So although widespread use of HMRs has limited cost-
effectiveness within the short-term, the targeted use of HMR for 
those patients most likely to benefit is likely to be cost-effective. 
Patients who benefit most from HMRs 
Within the literature, numerous Australian studies have been 
conducted that highlight distinct patient cohorts for whom 
provision of HMRs delivers significant health care savings, 
accompanied by improved patient outcomes.6,7,16 
This includes patients treated with warfarin, one of the leading 
medicines associated with hospital ADE-RAs.7 Patients provided 
with a HMR had a 79% reduction in their likelihood of next 
hospitalisation related to warfarin-associated bleeding, between 
Home Medicine Review program: overview 
Home Medicine Reviews (HMRs) assess a patient’s use of 
medicines. The main objective is to optimise quality use of 
medicines and reduce drug-related problems, including adverse 
drug effects (ADEs). Initiated by general practitioners (GPs) and 
facilitated by pharmacists, the program has been operational for 
over 12 years under Medicare.2 Currently, the program is funded 
under the 2010 Fifth Community Pharmacy Agreement (5CPA) 
between the Commonwealth and the Pharmacy Guild, which 
extends until 2015.2 Under the 5CPA, $15.4 billion has been 
allocated to community pharmacists, $663 million of which is for 
the delivery of professional services, including the HMR 
program.3 The HMR program specifically has an allocated budget 
of $52.11 million.4
Rationale for the latest changes 
Following the Pharmacy Guild’s strategy in 2010 to increase HMR 
uptake a higher than anticipated spike in demand for HMRs was 
observed towards the end of 2012.4 By 2013, the HMR program 
had exceeded its allocated budget by $4.2 million.4 Faced with 
finite resources and increasing demand, the most recent HMR 
changes were proposed to “ensure programme sustainability” by 
limiting HMR services and hence program spending.1 Although 
much of the allocated $52.11 million remains to be spent, the 
5CPA is up for renegotiation next year, and given the 
Commonwealth’s budgetary pressures, continual funding of 
HMRs is not guaranteed.4  
Clinical benefits of the HMR program 
The value of HMRs in improving patient safety through the 
minimisation of medication errors when targeted to patients at 
high risk has been demonstrated in retrospective cohort and 
implementation studies conducted in the Australian setting.5,6,7 
In Australia, a review of all hospital admissions studies 
highlighted that 2-3% (approximately 230 000) of admissions 
were medication-related.8,9 The associated annual costs of these 
ADE-related admissions (ADE-RAs) are estimated at $1.2 billion.9 
It is estimated that 50% of such admissions are preventable and 
that they account for up to 16% of emergency department 
admissions.10 The associated cost burden ADEs impose on 
primary care is uncertain, but observational studies of general 
practice activity have revealed that 11% of patients have 
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two- and six-months post-HMR.7 After six months, this benefit 
was not sustained. This indicates the need for more frequent 
monitoring, which may potentially include six-monthly reviews.7 
Such patients who are now faced with restricted access to HMRs 
may soon be placed at greater risk of warfarin-associated 
bleeding hospitalisations. 
Similarly, the application of HMRs to patients treated with heart 
failure medicines has been shown to be effective in delaying time 
to hospital readmission related to heart failure.6 Furthermore, 
numerous other medicines have been identified that increase 
the risk of hospital ADE-RAs, particularly for older people and 
these account for over 30% of hospital admissions in those aged 
75 years and over.17 
Such studies provide a foundation upon which policymakers and 
researchers can further build to better define which patients will 
gain the greatest benefit from HMRs at an acceptable cost.  
Alternatives to the new program framework 
HMR is by no means the only solution to preventing medication 
errors. Studies have demonstrated the potential value of post-
discharge collaborative management programs for patients 
prescribed warfarin, whereby other interventions such as point-
of-care International Normalised Ratio (INR) monitoring and 
warfarin education are integrated into the current HMR 
remuneration structure to promote the streamlined transition 
between tertiary and primary care.18 
Another way to optimise the benefits from HMRs on health care 
savings is to improve the timely delivery of HMRs. This can delay 
time to next hospitalisation and reduce ADE-related GP visits, 
particularly for those who are discharged from hospital and 
classified at high risk of medication misadventure.15 A potentially 
viable model of facilitating this involves hospital-initiated 
medication reviews (HIMRs).15 Although there is funding planned 
under the 5CPA for HIMRs, the current lack of available funding 
has created difficulties in rolling out such programs.15  
Conclusions 
There is much debate to be had over the implications of these 
recent HMR program changes for certain cohorts of patients and 
health care resources. The recent restrictions represent a 
generalised approach; however, current evidence for effective 
implementation of HMR for those most likely to benefit at an 
acceptable cost suggests that this is unlikely to meet the needs 
of those at greatest risk for ADEs. Thus, perhaps it would be 
more reasonable to consider exemption of particular cohorts of 
patients from these restrictions, particularly where there is 
evidence indicating significant health care savings or clinical 
benefit associated with the provision of HMRs on a more 
frequent basis. 
Although the current evidence does not provide stakeholders 
with all the answers about how best to restructure HMRs and 
whom to target, it does provide a solid basis on which to begin 
that process without unduly placing patients at risk.  
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